Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to $4.0 million.

  • InMed Pharmaceuticals' Shares Outstanding (Diluted Average) rose 45970.16% to $4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year increase of 45970.16%. This contributed to the annual value of $975985.0 for FY2025, which is 15612.84% up from last year.
  • InMed Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $4.0 million in Q4 2025, which was up 45970.16% from $4.0 million recorded in Q3 2025.
  • InMed Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $4.0 million during Q3 2025, with a 5-year trough of $166410.0 in Q3 2023.
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $663336.5 (2024), whereas its average is $1.3 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Shares Outstanding (Diluted Average) crashed by 8443.7% in 2024, and later skyrocketed by 53769.99% in 2025.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $566062.0 in 2022, then dropped by 29.57% to $398673.0 in 2023, then surged by 77.22% to $706546.0 in 2024, then soared by 459.7% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q4 2025, $4.0 million for Q3 2025, and $975985.0 during Q2 2025.